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Research in context
1. What is already known about this subject?
Cystic fibrosis related diabetes affects approxi-
mately 50% of people with cystic fibrosis over 
35 years of age and is increasingly prevalent as 
prognosis improves due to better treatment regi-
mens, nutritional support and management by a 
multidisciplinary team. Several previous publica-
tions have examined prevalence of microvascular 
complications related to cystic fibrosis-related 
diabetes. However, limited data are available for 
the same from the UK.
2. What is the key question?
•   What  is  the  prevalence  of  microvascular 
complications in cystic fibrosis-related 
diabetes in the United Kingdom?
3. What are the new findings?
•   In our  study, 22.7% people with  cystic 
fibrosis-related diabetes had microalbu-
minuria  and  17%  had  background 
retinopathy.
•   We found a higher frequency of microal-
buminuria compared with retinopathy in 
our cohort.
•   10.3% had absent foot pulse.
Retinopathy and microalbuminuria are 
common microvascular complications in 
cystic fibrosis-related diabetes
Punith Kempegowda , Harbinder Sunsoa, Joht S. Chandan, Lauren M. Quinn,  
Prashant M. Amrelia, Syed Noman Atta, Sidrah Amir, Yee Suh Teh,  
Sabba Chaudhry, Anne de Bray, Rifat Rashid, Joanna L. Whitehouse,  
Edward F. Nash and Ateeq Syed
Abstract
Aims: To study the prevalence of microvascular complications and renal changes associated 
with cystic fibrosis-related diabetes (CFRD).
Methods: This retrospective cohort study was conducted at the West Midlands Adult Cystic 
Fibrosis centre, United Kingdom. Data regarding age, sex, microalbuminuria, retinopathy 
neuropathy, and biochemical results were collected for all people with CFRD who had an 
annual review from 1 January 2018 to 31 December 2018 at the centre. Descriptive statistics 
were analysed using STATAv15.1.
Results: A total of 189 patients were included, of which 56.6% were male and median age 
(interquartile range) was 33 (27–39) years; 79.4% (150/189) had their annual review in 2018. 
Those with a biochemically impaired renal function numbered 7.2% (13/180) and 22.7% 
(32/141) had microalbuminuria; 17.2% (10/58) had diabetes related retinopathy. No one in our 
cohort had diabetic ulcers; however, 10.3% (13/126) had absent foot pulses.
Conclusion: We found a higher prevalence of microalbuminuria compared with retinopathy in 
a large cohort of cystic fibrosis adults. This study demonstrates the need for regular specialist 
follow-up to facilitate early identification of such complications and a long-term prospective 
cohort to understand underlying mechanisms.
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4.   How might these results change the focus of 
research or clinical practice?
•   Our study demonstrates need  for  regular 
specialist follow-up to facilitate early iden-
tification of microvascular complications 
in cystic fibrosis-related diabetes and a 
long-term prospective cohort to under-
stand underlying mechanisms.
Introduction
Cystic fibrosis (CF) is one of the most frequent 
autosomal recessive genetic conditions affecting 
Caucasians. It is caused by mutations in the cystic 
fibrosis transmembrane regulator gene, resulting 
in dysregulated chloride transport across epithe-
lial cell membranes. Consequently, mucus secre-
tions are thickened in multiple organ systems, 
including the lungs, pancreas, biliary tree and 
reproductive tract.1 The main causes of morbidity 
in CF are respiratory failure, due to progressive 
lung disease, and malnutrition, due to pancreatic 
exocrine insufficiency and malabsorption.2 
However, longer term sequelae of CF are being 
increasingly recognised, including bone disease 
and CF-related diabetes (CFRD).
CFRD affects approximately 50% of people with 
CF over 35 years of age3 and is increasingly preva-
lent as CF prognosis improves4 due to better 
 treatment regimens, nutritional support and man-
agement by a multidisciplinary team.5 CFRD is a 
distinct form of diabetes mellitus, but shares patho-
physiological features with both type 1 and type 2 
diabetes.6–8 It is principally caused by reduced insu-
lin secretion, arising secondary to reduced beta cell 
mass and beta cell dysfunction.9 The latter is caused 
by pancreatic ductal obstruction from viscous 
secretions and auto-digestion of pancreatic tissue 
from accumulation of exocrine enzymes. This 
results in fibrosis, fatty infiltration and beta cell 
loss.9 It is well recognised in people with CF that 
the first stage of insulin secretion is delayed, result-
ing in postprandial hyperglycaemia, which leads on 
to impaired glucose tolerance and eventual 
CFRD.7,10 Screening is essential because of the 
typically insidious onset of CFRD.6  Importantly, 
coexistence of diabetes with CF worsens pulmo-
nary function, shortens lifespan and confers 
increased morbidity and mortality, particularly in 
females.11 Pre-diabetes usually pre-dates a diagno-
sis of CFRD by up to 4–6 years.3,12 This highlights 
the importance of screening to minimise the delete-
rious consequences of hyperglycaemia and the 
detriment to lung function, nutrition and survival, 
before a diagnosis of CFRD is made.13
Glycosylated haemoglobin (HbA1c) should be 
tested annually and used for monitoring but is not 
recommended as a screening test, because of its 
poor sensitivity.3,14 Consensus guidelines there-
fore recommend that people with CF should be 
screened for CFRD using the oral glucose toler-
ance test (OGTT) at least annually from the age 
of 10 years and at times of pulmonary infective 
exacerbations when treated with steroids or dur-
ing work-up for lung transplantation. Although 
these  guidelines  acknowledge  that OGTT  is  an 
imperfect test due to the variability of both the 
test and the underlying condition, they recom-
mend OGTT as the screening test of choice.2,4
Guidelines recommend insulin as the preferred 
therapeutic agent3 because of its effectiveness in 
managing hyperglycaemia in addition to its anabolic 
effects, which improves lung function and nutri-
tional status.15 Furthermore, it is recommended 
that people with CFRD should have multi-discipli-
nary team follow-up (preferably four times per 
year), be offered diabetes structured education pro-
grammes and that HbA1c should be monitored 
with a target of <7% (<53 mmol/mol).3,5
Although macrovascular disease is currently 
rare,16 microvascular complications are increas-
ingly being recognised as complications of CFRD, 
particularly with increased duration of diabetes 
and poorer glycaemic control.17 Retinopathy, 
nephropathy and neuropathy are all recognised 
complications2,8 and prevalence of retinopathy has 
been reported from small studies as being equiva-
lent to rates observed in type 1 diabetes.18 Chronic 
kidney disease and microalbuminuria are also 
increasingly recognised in CF patients, for which 
CFRD is a strong risk factor.19 Contributing to 
this renal damage are combinations of administra-
tion of intravenous aminoglycosides for treatment 
of infective exacerbations and long-term immuno-
suppressive therapy following lung transplanta-
tion.19 Consensus guidelines therefore recommend 
annual screening for microvascular complications 
after 5 years of CFRD and frequent monitoring of 
risk factors: measuring blood pressure at each 
clinic appointment and annual lipid profiles.3 
Although microvascular complications are recog-
nised, reported prevalence differs and the risk fac-
tors associated with their development remain 
poorly understood.
P Kempegowda, H Sunsoa et al.
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The objective of the study was to evaluate the 
prevalence of microvascular complications in 
CFRD in a large UK cohort.
Methods
This retrospective study was done in the United 
Kingdom  in  2019.  All  people  with  CFRD who 
were registered in the West Midlands Adult Cystic 
Fibrosis Centre, University Hospitals Birmingham 
NHS Foundation Trust, Birmingham, UK were 
included for the study. We identified the study 
population from details in the outpatient attend-
ance for the cystic fibrosis centre. We had full 
access to the database of the study population. We 
did not use any other specific code for identifying 
the study population. The study did not involve 
any linkage of databases.
Clinical and biochemical parameters were collected 
from  1  January  2018  to  31  December  2018. 
Demographic information collected included age 
(years), gender and ethnicity. Clinical parameters 
included the most recent systolic and diastolic 
blood pressure recorded using an automatic blood 
pressure cuff (mmHg), height (cm), weight (kg) 
and body mass index (BMI) (kg/m2). Clinical notes 
and letters were reviewed to obtain duration of dia-
betes (years), current insulin therapy, oral anti-dia-
betes agents, presence or absence of hypoglycaemic 
episodes, evidence of lipodystrophy (including 
lipohypertrophy or lipoatrophy) and foot examina-
tion including manual palpation of peripheral 
pulses. Hypoglycaemia was classified into mild (self 
managed) or severe (requiring third party assis-
tance). Biochemical parameters were obtained 
from the most recent annual diabetes clinic review, 
including renal function [estimated glomerular fil-
tration rate (eGFR) and creatinine], liver function 
testing (albumin, gamma-glutamyl transferase 
(GGT), bilirubin, Alanine Transaminase (ALT), 
Alkaline Phosphatase (ALP) and total protein), 
lipid profiles [total cholesterol, triglycerides, high-
density lipoprotein (HDL) cholesterol, non-HDL 
cholesterol] and glycaemic control was measured 
using HbA1c (%, mmol/mol).
We assessed for the following microvascular com-
plications: microalbuminuria, retinopathy and 
neuropathy. Microalbuminuria was assessed by 
analysing the albumin–creatinine ratio (ACR) on 
an early morning urine sample from the most 
recent annual diabetes clinic appointment; the 
definition for microalbuminuria was in line with 
National Institute for Health and Care Excellence 
(NICE)  guidelines.20 Retinopathy screening 
attendance, images and reports were obtained 
from the UK national retinopathy annual screen-
ing programme. Diabetes-related retinopathy was 
graded as follows (in order of severity): no diabe-
tes-related retinopathy, background retinopathy, 
pre-proliferative retinopathy, proliferative retinop-
athy and maculopathy, and the worst grade of 
either eye was recorded. Neuropathy was evalu-
ated by physical examination, which included eval-
uation of sensation, motor function and autonomic 
changes. The physician who leads foot services in 
our hospital performed all foot examinations 
including manual palpation of peripheral pulses. 
The study was registered as a service evaluation 
audit with the department of clinical governance, 
University Hospitals Birmingham NHS Foundation 
Trust  (audit  approval  number:  4571).  Informed 
consent was waived as this was a retrospective data 
collection from patient case records. All data were 
anonymised at the stage of analysis and reporting.
Descriptive statistics were performed using 
STATA v. 15.1 and where analysis was con-
ducted to assess the difference between two 
groups, chi-squared and Wilcoxon rank-sum tests 
were conducted depending on whether the varia-
bles considered were categorical or continuous 
(as data were non-parametric) respectively. The 





included in the study. Median age was 32 years 
(interquartile  range  27–39)  and  56.6%  were 
male (n = 107/188).  Demographics,  clinical 
parameters and biochemical parameters are pre-
sented in Table 1. The annual review of 79.4% 
(150/189) took place in 2018. There were vary-
ing levels of missing data dependent on the 
parameters measured, which are also highlighted 
in Table 1.
CFRD treatment
Median  duration  of  diabetes  (130/189)  was 
8 years  (5–14 years)  and  median  HbA1c 
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(182/189) was 46 mmol/mol  (40–61 mmol/mol) 








insulin  only,  8.5%  (9/106)  on  mixed  insulin 
solution  and  2.8%  (3/106)  were  on  an  insulin 
pump.
Complications associated with CFRD
Forty-four  per  cent  (44/100)  had  experienced  at 
least one episode of mild hypoglycaemia in the pre-
ceding year. All these patients who experienced 
hypoglycaemia were treated with insulin for 
CFRD. None of our patients reported severe 
Table 1. Baseline characteristics of our cohort. Median age was 32 years (interquartile range 27–39). People in the cohort had body 
mass index within healthy range [median: 22 kg/m2 (21–26 kg/m2)]. Median systolic and diastolic blood pressure were also within 
normal range [123 mmHg (112–131 mmHg) and 78 mmHg (70–84 mmHg), respectively]. Their median lipid profiles were also within 
acceptable limits. We did not find any significant liver impairment in our cohort.
Number of records 
available (out of total 
cohort 189)




Age, years 188 32 27 39
Body mass index, cm/kg2 116 22 21 26
Height, cm 114 166 158 173
Weight, kg 134 64 55 73
Systolic blood pressure, mmHg 141 123 112 131
Diastolic blood pressure, mmHg 141 78 70 84
Glycated haemoglobin, %, mmol/mol 182 6.4 (46) 5.8 (40) 8 (63)
Cholesterol, mmol/l 173 4 3 4
Triglycerides, mmol/l 168 1 1 2
High density lipoprotein, mmol/l 159 1 1 2
Low density lipoprotein, mmol/l 158 2 1 2
Non-high density lipoprotein, mmol/l 154 2 2 3
Bilirubin, µmol/l 182 8 5 12
Alanine transaminase, IU/l 182 21 15 32
Alkaline phosphatase, IU/l 182 116 84 150
Gamma-glutamyl transferase, IU/l 167 23 15 43
Albumin, g/l 182 36 32 39
Total protein, g/l 183 72 67 76
Estimated glomerular filtration rate, ml/min per 1.73 m2 180 85 71 90
Creatinine, µmol/l 183 67 57 79
Albumin–creatinine ratio, mg/mmol 141 1 0 3
P Kempegowda, H Sunsoa et al.
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had evidence of attending screening and we had 
results for 58 people with CFRD in our cohort. We 
compared those who had retinopathy screening 
(n = 72)  with  the  remainder  of  the  population 
(n = 117)  and  found  no  significant  differences 
between the groups in terms of age, gender, diabe-
tes duration and control, and insulin therapy use 
(Table 2). Of those who had recorded retinopathy 
screening,  17.2%  (10/58)  had  some  form  of 
 diabetic eye disease (retinopathy or maculopathy). 
The severity of eye changes was graded using 
National Screening Committee Criteria for retin-
opathy  (R0  –  None,  R1  –  Background,  R2  – 
 Pre-proliferative, R3 – Proliferative), maculopathy 
(M0 – nil present, M1 – maculopathy), Photoco-
agulation (P) and Unclassifiable (U).21 Seven 
patients had background retinopathy (R1 M0 
worst eye), treated proliferative retinopathy (right 
eye: R1 M0, left eye: R3s M0) in one patient, pre-
proliferative retinopathy and maculopathy (right 
eye: R2 M1, left eye: R2 M0) in one patient and 
only maculopathy (right eye: R0 M0, left eye: R0 
M1) in one patient. People with retinopathy were 
younger and predominantly male compared with 
those without retinopathy (Table 3).
Median eGFR, creatinine and ACR were 85 (71–
90) ml/min per 1.73 m2, 67  (57–79) μmol/l and 
0.9  (0–2.6)  mg/mmol  respectively.  Renal  func-
tion was biochemically impaired in 7.2% (13/180) 
(eGFR <60 ml/min  per  1.73 m2).  Interestingly, 
22.7%  (32/141)  had  microalbuminuria.  One 
Table 2. Difference in baseline characteristics and management of cystic fibrosis-related diabetes between 
people who had retinopathy screening and the rest of the cohort. There were no significant differences 
between the groups in terms of age, gender, diabetes duration and control, and insulin therapy use.
Patients with retinopathy 
screening
Total n = 72
Patients without diabetic 
retinopathy screening
Total n = 117
p-value
Age, years 33 (28–39) 32 (27–39) 0.4981
Gender, % male 40/72 (56%) 67/116 (58%) 0.767
Diabetes duration, years 9 (5–15) 8 (5–13) 0.3244
Insulin therapy, yes/no 42/72 (58%) 64/117 (55%) 0.625
HbA1c, % 6.8 (5.9–7.9) 6.3 (5.8–7.4) 0.3239
HbA1c, glycosylated haemoglobin.
Table 3. Comparing the demographics and clinical characteristics between those with and without 
retinopathy. People with retinopathy were younger and predominantly male compared with those without 
retinopathy.
People with CFRD and 
retinopathy
n = 10




Age, years 27 (25–33) 33 (28–39) 0.0621
Gender, % male 9/10 (90%) 27/48 (56%) 0.045
Diabetes duration, years 9 (7–22) 9 (5–15) 0.5123
Insulin therapy, yes/no 5/10 (50%) 28 (58%) 0.6313
HbA1c, %) 7.1 (6.0–8.8) 7.1 (6.0–7.9) 0.625
CFRD, cystic fibrosis-related diabetes; HbA1c, glycosylated haemoglobin.
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study  subject  had  macroalbuminuria  (410 mg/
mmol). Table 4 compares the demographic and 
clinical information between those with and with-
out microalbuminuria.
None of our study cohort had neuropathy and 
there were no diabetes-related foot ulcers (189/189 
examined and notes reviewed). However, 10.3% 




their annual review performed but datasets for the 
biochemical and retinal screening were incom-
plete. A longitudinal study by Scheuing et  al.22 
compared received care with guideline standards 
in people with CFRD3 and showed that HbA1c, 
BMI  and  lipid  profile were  tested  at  least  once 
annually 88.8%, 86.5% and 79.5% of  the  time. 
People with CFRD were screened for retinopathy 
or  microalbuminuria  29.9%  and  33.2%  of  the 
time  respectively,  but  overall  only  7.9%  had  a 
complete set of examinations which would meet 
all guideline standards.22 This demonstrates the 
low adherence to guidelines for people with 
CFRD, which can be explained by the context of 
burdensome treatment regimens and frequent 
hospital attendances for people with CF. 
Nevertheless, CFRD warrants optimal care, a 
multidisciplinary team approach and close moni-
toring for complications in order to prevent harm.
Frequent hypoglycaemic episodes can suppress 
hypoglycaemic awareness, increasing risk of 
severe hypoglycaemic episodes, and adversely 
affect quality of life.23,24 Therefore, monitoring 
and characterisation of hypoglycaemia in CFRD 
patients is important, but challenges remain 
because continuous glucose monitoring is not 
routinely available for this cohort. Nevertheless, 
our  finding  that  44%  of  our  CFRD  cohort 
reported non-severe hypoglycaemia at their 
annual review highlights the importance of a mul-
tidisciplinary team approach to optimise diabetes 
management in CFRD.
The majority of our cohort did not attend for 
annual eye screening in the period studied and of 
those who did, 17% had evidence of retinopathy 
or maculopathy. Roberts et  al.17 performed a 
cross-sectional analysis in a Welsh cohort of peo-
ple with insulin treated CFRD to assess retinopa-
thy (using digital photography) and retinal 
screening  attendance.  In  their  cohort,  36%  of 
patients did not attend for their retinal screening 
appointment in the year assessed, but of those 
who did, 42% had evidence of retinopathy, rang-
ing from mild to proliferative, and associated with 
maculopathy.17 Choudhury et  al.25 performed a 
retrospective seven-year longitudinal study in this 
same Welsh cohort and demonstrated  that 44% 
of screened people with CFRD had retinopathy.25 
Yung et al.26 found retinopathy in 16% and 23% 
of a small cohort of patients at 5 years and 10 years 
of CFRD respectively, but HbA1c was not sig-
nificantly different between people with and with-
out retinopathy.26 Andersen et  al. also reported 
retinopathy in 36% of insulin-treated people with 
10 years’ duration of CFRD.18 The lower fre-
quency of retinopathy observed in our cohort 
Table 4. Comparing the demographics and clinical characteristics between those with and without 
microalbuminuria. People with microalbuminuria were older than those without microalbuminuria; otherwise 
there was no significant difference between the two groups.
People with CFRD and 
microalbuminuria
n = 32




Age, years 38 (32–47) 32 (27–39) 0.0072
Gender, % male 18/32 (56%) 58 (54%) 0.8
Diabetes duration, years 12 (4–19) 8 (5–13) 0.0695
Insulin therapy, yes/no 22 (69%) 67 (62%) 0.488
HbA1c, % 6.7 (6.0–8.0) 6.3 (5.8–7.7) 0.2514
CFRD, cystic fibrosis-related diabetes; HbA1c, glycosylated haemoglobin.
P Kempegowda, H Sunsoa et al.
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could be due to inclusion of non-insulin-users 
and lower median HbA1c compared with the 
cohorts  assessed  in  these other  series  [46 mmol/
mol (6.4%) versus 61 mmol/mol (7.7%) in Roberts 
et al.17], despite similar duration of diabetes. Our 
study therefore reflects better glycaemic control, 
but retinal disease remained prevalent despite 
this. Further studies with larger cohorts and serial 
follow-up are needed to confirm these findings.
Microalbuminuria has long been associated with 
increased risk of developing chronic kidney disease 
(CKD).27–29  In  a  seven-year  longitudinal  study, 
Quon et  al.30  found  2.4-fold  increased  risk  for 
developing CKD in CFRD patients treated with 
insulin for 1–4 years.30 Berg et al.31 in a cross-sec-
tional analysis showed that concomitant moderate 
CKD in CF was not only significantly associated 
with higher prevalence of CFRD (p < 0.001), but 
also increased cumulative intravenous aminogly-
coside usage (p < 0.005), advancing age (p < 0.001) 
and longer duration of chronic pulmonary infec-
tions (p < 0.008).31 As we demonstrate that micro-
albuminuria represents a frequent complication of 
CFRD, this warrants annual monitoring but must 
be interpreted with caution because microalbumi-
nuria may be falsely elevated with antibiotics, 
severe illness or physical stress.32
We observed a relatively higher frequency of 
microalbuminuria compared with retinopathy in 
our cohort. This is in keeping with a study per-
formed by Van den berg et al.,33 who compared 
microvascular complications in CFRD with peo-
ple with type 1 diabetes in a combined UK and 
Netherlands cohort. They showed that people 
with CFRD were significantly more likely to 
develop microalbuminuria (21% versus  4.1%, 
p = 0.003) and less likely to develop retinopathy 
(10% versus 24%, p = 0.044) compared with type 
1 diabetes matched controls.33 Lind-Ayres et al.34 
showed in their study that the odds of developing 
permanent microalbuminuria were seven times 
higher  in CFRD and 48  times higher with con-
comitant lung or liver transplantation.34
Although there was no evidence of diabetes-
related foot ulcers in our cohort, 10.3% had 
absent peripheral foot pulses, a finding which, to 
our knowledge, has not been previously reported. 
All these patients were referred to vascular surgi-
cal review for further assessment. We did not 
record the results for this review. Vascular insuf-
ficiency was not objectively verified as this finding 
could indicate macroangiopathy, which warrants 
further investigation. Clubbing is pathognomonic 
of CF and hypertrophic osteoarthropathy of the 
hands and toes arises secondary to hypoxia, 
inflammation and abnormal vascularisation in 
CF patients.35,36 In future work, we would need 
to compare our CFRD cohort with matched non-
CFRD controls to determine whether macroangi-
opathy is additionally accountable for the vascular 
insufficiency observed.
Limitations
Despite the large sample size studied here, there 
are a few limitations for this study. None of the 
people in our cohort had a renal biopsy, and 
therefore it was not possible to diagnose diabetes-
related  nephropathy  on  pathology.  In  addition, 
retinal screening and microalbuminuria were 
incomplete, rendering it difficult to establish 
accurate frequencies of microvascular complica-
tions. Also, of note is that the difference in the 
sample sizes of our cohorts for microalbuminuria 
and retinopathy are different, which may have 
some influence on the results. We also have 
recorded microalbuminuria based on analysing 
the ACR on an early morning urine sample, in 
line with NICE guidelines.20 We note that CFRD 
guidelines recommend that microalbuminuria 
should be made if two out of three tests are abnor-
mal within  a 3–6-month period3 and hence our 
results may need further validation. We do not 
have history of any organ transplantation for our 
cohort. Additionally, we were not able to explore 
blood glucose measurements and variability, or 
adherence to treatment, transplantation status, 
haemoglobin level, number of hospital admis-
sions, intravenous aminoglycoside treatment (fre-
quency or duration), drug history, exercise, or 
lung function testing. These factors are important 
because they can contribute to transient microal-
buminuria. Further, lack of confirmatory tests for 
vascular insufficiency limits the extrapolation of 
these findings.
Conclusion
We found a higher frequency of microalbuminu-
ria compared with retinopathy in a large cohort 
of CF adults. Exposure to aminoglycosides as 
part of CF treatment might explain the higher 
frequency of microalbuminuria, yet not in 
entirety. We suggest that future research should 
assess additional potential risk factors for 
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microalbuminuria. Longitudinal studies are also 
needed to assess the development of long-term 
diabetes-related comorbidities in people with 
CFRD, given the prevalence. Overall, our study 
demonstrates that people CFRD are at risk of 
microvascular disease, confirming the need for a 
multi-disciplinary team approach for judicious 
screening and monitoring to minimise the devel-
opment of microalbuminuria and retinopathy in 
people with CFRD.
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